Literature DB >> 20031278

Cognitive effects of cell-derived and synthetically derived Aβ oligomers.

Miranda N Reed1, Jacki J Hofmeister, Lisa Jungbauer, Alfred T Welzel, Chunjiang Yu, Mathew A Sherman, Sylvain Lesné, Mary Jo LaDu, Dominic M Walsh, Karen H Ashe, James P Cleary.   

Abstract

Soluble forms of amyloid-β peptide (Aβ) are a molecular focus in Alzheimer's disease research. Soluble Aβ dimers (≈8 kDa), trimers (≈12 kDa), tetramers (≈16 kDa) and Aβ*56 (≈56 kDa) have shown biological activity. These Aβ molecules have been derived from diverse sources, including chemical synthesis, transfected cells, and mouse and human brain, leading to uncertainty about toxicity and potency. Herein, synthetic Aβ peptide-derived oligomers, cell- and brain-derived low-n oligomers, and Aβ*56, were injected intracerebroventricularly (icv) into rats assayed under the Alternating Lever Cyclic Ratio (ALCR) cognitive assay. Cognitive deficits were detected at 1.3 μM of synthetic Aβ oligomers and at low nanomolar concentrations of cell-secreted Aβ oligomers. Trimers, from transgenic mouse brain (Tg2576), did not cause cognitive impairment at any dose tested, whereas Aβ*56 induced concentration-dependent cognitive impairment at 0.9 and 1.3μM. Thus, while multiple forms of Aβ have cognition impairing activity, there are significant differences in effective concentration and potency. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20031278      PMCID: PMC2895944          DOI: 10.1016/j.neurobiolaging.2009.11.007

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  26 in total

1.  Solution state characterization of amyloid beta-derived diffusible ligands.

Authors:  Robert W Hepler; Karen M Grimm; Deborah D Nahas; Robert Breese; Elizabeth Chen Dodson; Paul Acton; Paul M Keller; Mark Yeager; Hui Wang; Paul Shughrue; Gene Kinney; Joseph G Joyce
Journal:  Biochemistry       Date:  2006-12-06       Impact factor: 3.162

2.  Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins.

Authors:  M P Lambert; A K Barlow; B A Chromy; C Edwards; R Freed; M Liosatos; T E Morgan; I Rozovsky; B Trommer; K L Viola; P Wals; C Zhang; C E Finch; G A Krafft; W L Klein
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-26       Impact factor: 11.205

3.  Neurotoxic protein oligomers--what you see is not always what you get.

Authors:  Gal Bitan; Erica A Fradinger; Sean M Spring; David B Teplow
Journal:  Amyloid       Date:  2005-06       Impact factor: 7.141

4.  Orally available compound prevents deficits in memory caused by the Alzheimer amyloid-beta oligomers.

Authors:  Matthew Townsend; James P Cleary; Tapan Mehta; Jacki Hofmeister; Sylvain Lesne; Eugene O'Hare; Dominic M Walsh; Dennis J Selkoe
Journal:  Ann Neurol       Date:  2006-12       Impact factor: 10.422

Review 5.  The role of cell-derived oligomers of Abeta in Alzheimer's disease and avenues for therapeutic intervention.

Authors:  D M Walsh; I Klyubin; G M Shankar; M Townsend; J V Fadeeva; V Betts; M B Podlisny; J P Cleary; K H Ashe; M J Rowan; D J Selkoe
Journal:  Biochem Soc Trans       Date:  2005-11       Impact factor: 5.407

6.  Amyloid-beta1-42 reduces neuronal excitability in mouse dentate gyrus.

Authors:  Sung Hwan Yun; Georgi Gamkrelidze; W Blaine Stine; Patrick M Sullivan; Joseph F Pasternak; Mary Jo Ladu; Barbara L Trommer
Journal:  Neurosci Lett       Date:  2006-06-12       Impact factor: 3.046

7.  Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function.

Authors:  James P Cleary; Dominic M Walsh; Jacki J Hofmeister; Ganesh M Shankar; Michael A Kuskowski; Dennis J Selkoe; Karen H Ashe
Journal:  Nat Neurosci       Date:  2004-12-19       Impact factor: 24.884

8.  Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice.

Authors:  K Hsiao; P Chapman; S Nilsen; C Eckman; Y Harigaya; S Younkin; F Yang; G Cole
Journal:  Science       Date:  1996-10-04       Impact factor: 47.728

Review 9.  A beta oligomers - a decade of discovery.

Authors:  Dominic M Walsh; Dennis J Selkoe
Journal:  J Neurochem       Date:  2007-02-05       Impact factor: 5.372

10.  Appearance of sodium dodecyl sulfate-stable amyloid beta-protein (Abeta) dimer in the cortex during aging.

Authors:  M Enya; M Morishima-Kawashima; M Yoshimura; Y Shinkai; K Kusui; K Khan; D Games; D Schenk; S Sugihara; H Yamaguchi; Y Ihara
Journal:  Am J Pathol       Date:  1999-01       Impact factor: 4.307

View more
  62 in total

1.  Structure-activity relationships in peptide modulators of β-amyloid protein aggregation: variation in α,α-disubstitution results in altered aggregate size and morphology.

Authors:  Cyrus K Bett; Johnpeter N Ngunjiri; Wilson K Serem; Krystal R Fontenot; Robert P Hammer; Robin L McCarley; Jayne C Garno
Journal:  ACS Chem Neurosci       Date:  2010-07-08       Impact factor: 4.418

Review 2.  The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes.

Authors:  Iryna Benilova; Eric Karran; Bart De Strooper
Journal:  Nat Neurosci       Date:  2012-01-29       Impact factor: 24.884

Review 3.  The intersection of amyloid beta and tau at synapses in Alzheimer's disease.

Authors:  Tara L Spires-Jones; Bradley T Hyman
Journal:  Neuron       Date:  2014-05-21       Impact factor: 17.173

4.  Therapeutic molecules and endogenous ligands regulate the interaction between brain cellular prion protein (PrPC) and metabotropic glutamate receptor 5 (mGluR5).

Authors:  Laura T Haas; Mikhail A Kostylev; Stephen M Strittmatter
Journal:  J Biol Chem       Date:  2014-08-22       Impact factor: 5.157

5.  Clustering of sialylated glycosylphosphatidylinositol anchors mediates PrP-induced activation of cytoplasmic phospholipase A 2 and synapse damage.

Authors:  Clive Bate; Alun Williams
Journal:  Prion       Date:  2012-08-16       Impact factor: 3.931

Review 6.  The neurodegeneration in Alzheimer disease and the prion protein.

Authors:  Gianluigi Forloni; Alessandra Sclip; Tiziana Borsello; Claudia Balducci
Journal:  Prion       Date:  2013-01-01       Impact factor: 3.931

7.  Endocytic pathways mediating oligomeric Abeta42 neurotoxicity.

Authors:  Chunjiang Yu; Evelyn Nwabuisi-Heath; Kevin Laxton; Mary Jo Ladu
Journal:  Mol Neurodegener       Date:  2010-05-17       Impact factor: 14.195

8.  The culprit behind amyloid beta peptide related neurotoxicity in Alzheimer's disease: oligomer size or conformation?

Authors:  Kerensa Broersen; Frederic Rousseau; Joost Schymkowitz
Journal:  Alzheimers Res Ther       Date:  2010-07-14       Impact factor: 6.982

9.  Correlation of specific amyloid-β oligomers with tau in cerebrospinal fluid from cognitively normal older adults.

Authors:  Maureen Handoko; Marianne Grant; Michael Kuskowski; Kathleen R Zahs; Anders Wallin; Kaj Blennow; Karen H Ashe
Journal:  JAMA Neurol       Date:  2013-05       Impact factor: 18.302

10.  Alzheimer's disease: synaptic dysfunction and Abeta.

Authors:  Ganesh M Shankar; Dominic M Walsh
Journal:  Mol Neurodegener       Date:  2009-11-23       Impact factor: 14.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.